Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab in Combination With Other Anti-cancer Treatments in Multiple Myeloma
NCT05090566Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Oct 2021
- Primary completion
- Feb 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of elranatamab in multiple myeloma (MM) (2 arms), sponsored by Pfizer. Primary endpoint: Dose Limiting Toxicities at 42 days. Started Oct 2021; status: terminated.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05090566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05090566.